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James J Galligan1 and Dennis R Petersen2*Abstract
Enzyme-mediated disulfide bond formation is a highly conserved process affecting over one-third of all eukaryotic
proteins. The enzymes primarily responsible for facilitating thiol-disulfide exchange are members of an expanding
family of proteins known as protein disulfide isomerases (PDIs). These proteins are part of a larger superfamily of
proteins known as the thioredoxin protein family (TRX). As members of the PDI family of proteins, all proteins
contain a TRX-like structural domain and are predominantly expressed in the endoplasmic reticulum. Subcellular
localization and the presence of a TRX domain, however, comprise the short list of distinguishing features required
for gene family classification. To date, the PDI gene family contains 21 members, varying in domain composition,
molecular weight, tissue expression, and cellular processing. Given their vital role in protein-folding, loss of PDI
activity has been associated with the pathogenesis of numerous disease states, most commonly related to the
unfolded protein response (UPR). Over the past decade, UPR has become a very attractive therapeutic target for
multiple pathologies including Alzheimer disease, Parkinson disease, alcoholic and non-alcoholic liver disease, and
type-2 diabetes. Understanding the mechanisms of protein-folding, specifically thiol-disulfide exchange, may lead to
development of a novel class of therapeutics that would help alleviate a wide range of diseases by targeting the
UPR.
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Increasing evidence supports an important role for mis-
folded proteins in the pathogenesis of numerous diseases
including diabetes, Alzheimer disease, Parkinson disease,
and both alcoholic and non-alcoholic liver disease [1].
Accumulation of misfolded proteins (or erred protein
load) is generally caused by either decreased disposal of
erred protein or a decrease in the correct folding of pro-
teins [1]. Disulfide bond formation represents a funda-
mentally important post-translational modification that
is a critical step in the folding of nascent peptides in the
endoplasmic reticulum (ER) [2]. These covalent linkages
are formed between the side-chains of cysteine residues
and represent a key rate-limiting step in protein matur-
ation [3]. The enzymatic formation, breakage, and subse-
quent rearrangement of cysteine linkages are crucial to
protein structure and function and primarily mediated* Correspondence: Dennis.Petersen@UCDenver.edu
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distribution, and reproduction in any mediumby members of the protein disulfide isomerase (PDI)
family [4]. All genes in the PDI family are part of a
superfamily referred to as the thioredoxin (TRX) super-
family, which also includes the glutaredoxins, TRXs, fer-
roredoxins, and peroxidoxins [5].
The PDI gene family currently comprises 21 genes,
varying in size, expression, localization, and enzymatic
function. Although it is implied that all members of the
PDI family possess the ability to rearrange disulfide
bonds, only a subset is considered orthologous and able
to carry out these reactions, with the other members
being paralogous and linked to the family through evolu-
tion, not function [4]. While these proteins may be func-
tionally different, the unifying feature of all PDI family
members is the presence of a TRX-like domain [2].
These may be present as either a catalytically active a or
a’ domain (the presence of a CXXC motif ) or a catalytic-
ally inactive b or b’ domain (for a more detailed review
on the precise role of these domains, see the work of Ell-
gaard et al.) [2,4]. Extensive research has assessed the
roles of these domains and revealed the b’ domain to bed Central Ltd. This is an Open Access article distributed under the terms of the
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vious literature has highlighted the features of a number
of PDI family members; however, with an increasing
amount of cDNA and EST sequence information depos-
ited in the NCBI database, a composite review is
required to further characterize and compare all 21
current members of the PDI gene family (Table 1).
Domain composition of the PDI family proteins
Proteins in the PDI family are largely expressed in the
ER, although few family members have been detected in
other subcellular compartments [6]. Due to their
localization, the presence of a short NH2-terminal signal
peptide exists in all members of the family. These pep-
tides are typically 15–30 amino acids (a.a.) in length and
are cleaved upon entry into the ER [7]; this has led to
some sequence discrepancy among multiple PDI pro-
teins. As indicated, the common thread between all
members of the PDI proteins is the presence of at least
one TRX-like domain, whether it is catalytically active
(a) or inactive (b) [2]. The active site of the a-type
domains also varies greatly, with the “classical” motif




AGR2 XAG-2, HAG-2, AG2, PDIA17 Anterior
AGR3 HAG3, hAG-3, BCMP11, PDIA18 Anterior
CASQ1 PDIB1 Calseque
CASQ2 PDIB2 Calseque
DNAJC10 MTHr, ERdj5 DnaJ (H
10
ERP27 FLJ32115, ERp27, PDIA8 Endopla
ERP29 ERp28, ERp31, ERp29, PDI-DB, PDIA9 Endopla
ERP44 KIAA0573, PDIA10 Endopla
P4HB DIA1, PROHB, DSI, GIT, PDI, PO4HB, P4Hb Protein d
PDIA2 PDA2, PDIp Protein d
PDIA3 P58, ERp61, ERp57, ERp60, GRP57, PI-PLC, HsT17083 Protein d
PDIA4 ERP70, ERP72 Protein d
PDIA5 PDIR, FLJ30401 Protein d
PDIA6 P5, ERp5 Protein d
PDILT PDIA7, ERp65 Protein
testis
TMX1 TMX, PDIA11 Thioredo
TMX2 PDIA12 Thioredo
TMX3 FLJ20793, KIAA1830, PDIA13 Protein d
TMX4 DJ971N18.2, KIAA1162, PDIA14 Thioredo
TXNDC5 MGC3178, FLJ21353, FLJ90810, EndoPDI, Hcc-2, ERp46,
PDIA15
Thioredo
TXNDC12 TLP19, ERP18, ERP19, hAG-1, AGR1, PDIA16 Thioredo
DNAJC10 has been included following identification of this gene in the PDI gene faresidues in these active sites are considered redox active,
undergoing active shuffling of disulfide bonds [2]. The
surrounding a.a. largely play a role in the regulation of
the pKa of the cysteines, dictating the local redox poten-
tial and thus regulating the catalytic ability of these
cysteines to actively oxidize or reduce disulfide bonds
(for a more comprehensive review on the redox poten-
tial of PDI, see the work of Hatahet et al.) [3]. Extensive
biochemical and biophysical experimentation has taken
place analyzing TRX–like domain containing proteins;
however, a complete crystal structure is currently not
available for most family members. Another common
characteristic of the PDI family of proteins is the pres-
ence of a COOH-terminal ER retention sequence com-
prised of a Lys-Asp-Glu-Leu-like sequence [2]. Whereas
these sequences may differ greatly in a.a. composition,
only four PDI proteins do not contain this sequence.
Figure 1 shows the domain composition of the 21 pro-
teins in the PDI family.
Evolutionary divergence of the PDI gene family
As mentioned, all genes encompassed in the PDI family





gradient protein 2 homolog 7p21.3 175
gradient protein 3 homolog 7p21.1 166
strin-1 1q21 396
strin-2 1p13.3-p11 399
sp40) homolog, subfamily C, member2q32.1 793
smic reticulum resident protein 27 12p12.3 273
smic reticulum resident protein 29 12q24.13 261
smic reticulum resident protein 44 9q22.33 406
isulfide-isomerase 17q25 508
isulfide-isomerase A2 16p13.3 525
isulfide-isomerase A3 15q15 505
isulfide-isomerase A4 7q35 645
isulfide-isomerase A5 3q21.1 519
isulfide-isomerase A6 2p25.1 440
disulfide-isomerase-like protein of the16p12.3 584
xin-related transmembrane protein 1 14q22.1 280
xin-related transmembrane protein 2 11cen-q22.3 296
isulfide-isomerase TMX3 18q22 454
xin-related transmembrane protein 4 20p12 349
xin domain-containing protein 5 6p24.3 432
xin domain-containing protein 12 1p32.3 172
mily. Synonyms of these genes have also been corrected.
Figure 1 Schematic representation of the domain compositions of the 21 proteins in the PDI gene family. All proteins contain a short
NH2-terminal signal sequence designated in black. Catalytically active TRX-like domains (a or a’) are represented in red with active sites noted;
inactive TRX domains in blue (b) and purple (b’); green represents the Asp/Glu rich Ca2+-binding domains; linker regions (gray); transmembrane
domains (yellow); COOH-terminal ER-retention sequences in white with a.a. composition denoted. Although ERP29 does contain an a-like domain,
this is based on homology and not catalytic efficiency. Sequences and domain compositions were acquired and verified from the National Center
for Biotechnology Information (NCBI) database. Figure was adapted and modified from [4].
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one TRX-like domain, whether this be catalytically active
(a or a’) or inactive (b or b’) [4]. These domains contain
a TRX structural fold that has amino acids arranged in a
conserved three-dimensional conformation [8]. While
the enzymatic function of these domains is not con-
served, the current theory proposes that all PDI family
members evolved through domain duplications from an
ancestral prokaryotic PDI which contained a single TRX
domain [9]. Although all human PDIs possess a TRX-
like domain, this remains one of the few similarities be-
tween these proteins, differing greatly in molecular mass
and a.a. composition outside of the TRX fold. Phylogen-
etic analysis, presented as a dendrogram in Figure 2,
outlines the evolutionary divergence of the human PDI
proteins. Sequence analysis reveals a subset of genes
within this family that are evolutionarily related, as
shown by the calsequestrin (CASQ) and anterior gradi-
ent (AGR) branches (in red and blue, respectively). Sup-
porting the hypothesis that these subsets of genes are
phylogenetically related, a high degree of similarity was
also observed with both domain architecture (Figure 1)
and sequence identity (Table 2). Although similarities
are evident, the overall homology between the proteins
is quite minimal. This is supported by previous attemptsto cluster large sets of both eukaryotic and prokaryotic
PDIs where marginal resolution of PDI domains was also
observed [9]. Given the broad spectrum of both enzym-
atic functions and domain compositions, it is not sur-
prising that the proteins share little sequence homology
with one another (Table 2).
The human PDI gene family
DNAJC10
The DNAJC10 gene is located at Chr 2q32.1 and
encodes the 793-a.a. DNAJC10 protein (also commonly
known as ERdj5 or MTHr) [10]. The DNAJC10 gene
consists of 3483 bp; transcription of two splice variants
has been identified due to a skipped exon, resulting in a
138-bp (46 a.a.) absence, present between nucleotides
1243 and 1244 [10]. To date, a total of four missense
single-nucleotide polymorphisms (SNPs) have been
reported for ERdj5, located at a.a. 76 (Asp!Asn), 347
(Leu! Ile), 414 (Tyr!Cys) and 646 (His!Gln); ERdj5
also contains one potential Asn-linked glycosylation site,
present at a.a. 530. Like other PDI family members, the
DNAJC10 promoter region contains a putative ER stress
element (ERSE) box, yielding gene induction following
ER stress [11]. Expression patterns of DNAJC10 revealed
ubiquitous expression with varying intensities and high
Figure 2 Clustering dendrogram of the human PDI gene family. Utilizing ClustalW alignment software of known protein sequences of the
human PDI genes reveals divergence into AGR and CASQ subfamilies (red and blue, respectively).
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creas and testis [10,11]. In addition to the PDI family,
DNAJC10 is also a member of the ERdj family, being
comprised of an unverified NH2-terminal signal peptide
(32 a.a.), one DnaJ domain (which plays a major role in
protein folding), five TRX domains (one b and four a type
domains, active sites Cys-Ser-His-Cys, Cys-Pro-Pro-Cys,
Cys-His-Pro-Cys, and Cys-Gly-Pro-Cys), and a COOH-
terminal ER retention sequence (Lys-Asp-Glu-Leu) [10,12].
Despite the high number of TRX domains, DNAJC10 was
found to possess roughly one-third the activity of P4HB
and displayed no oxidase or isomerase activity [12]. These
results were found to reflect an apparent redox equilibrium
constant of 190 mM, roughly 100 times more reducing
than that of the ER [12].
ERP27
Currently, little is known about the precise role and
function of ERP27. ERP27 was discovered in 2006 fol-
lowing a database search for novel human PDI family
members [13]. The ERP27 gene has been mapped to Chr
12p12.3 and encodes the 273-a.a protein. The ERP27
protein contains a cleavable NH2-terminal signal se-
quence, leaving the mature protein to be 248 a.a, begin-
ning at Glu-26 [13]. ERP27 does not contain a redox
active Cys-X-X-Cys TRX motif, however, the protein
does contain one b and one b’ type domains and an ER
retention sequence (Lys-Val-Glu-Leu) [13]. ERP27 was
also found to directly interact with another PDI family
member, PDIA3 [13]. Expression of ERP27 is fairlyubiquitous, with highest expression found in pancreas
[13]. To date, no knockout studies have been conducted
and future studies are needed to fully understand the
function and role of ERP27.
ERP29
The ERP29 gene is located at Chr 12q24.13 and may
represent a gene-duplication event with ERP27, given
their close proximity. ERP29 encodes a protein of 261 a.
a. termed ERP29 (also known as ERP28). In a compre-
hensive study of the genomic organization of ERP29,
Sargsyan et al. studied a 5′-flanking region consisting of
~2 kb, 3 exons, 2 introns and a 3′-flanking region of
0.31 kb [14]. ERP29 contains an NH2-terminal signal
peptide (32 a.a.), one a type TRX domain and a COOH-
terminal ER-retention sequence (Lys-Glu-Glu-Leu) [15].
While the presence of one a type domain is present,
ERP29 is unique in that it does not contain an active-
site motif; assignment of the TRX domain is placed
strictly on sequence homology with the a-type TRX do-
main, not on the activity of the domain. ERP29 contains
two potential phosphorylation sites, both located on
tyrosine residues, located at a.a. 64 and 66. ER
localization of ERP29 was also confirmed using im-
munofluorescence and subcellular fractionation [15].
ERP29 is ubiquitously expressed with high levels being
found in secretory tissues as well as the prostate, pan-
creas, and liver [14,16]. Although ERP29 lacks any iden-
tified ERSE in its promoter region, ERP29 is described as
an ER stress-inducible protein and has been shown to
Table 2 Amino acid similarity between human PDI proteins, as reported using EMBOSS Water Pairwise Alignment Algorithm (http://www.ebi.ac.uk/Tools/psa/
emboss_water/)






CASQ2 15.3% 17.40% 68.4%
(37.4%) (34.0%) (86.1%)
DNAJC10 16.2% 19.0% 16.8% 18.2%
(37.2%) (35.8%) (33.3%) (33.3%)
ERP27 28.2% 20.5% 17.2% 19.3% 18.6%
(41.0%) (40.2%) (34.4%) (37.6%) (35.8%)
ERP29 20.6% 23.3% 18.2% 20.4% 18.1% 15.7%
(40.2%) (39.5%) (31.1%) (33.0%) (30.9%) (38.9%)
ERP44 22.2% 26.5% 19.2% 20.0% 20.4% 24.3% 25.3%
(39.4%) (47.0%) (42.9%) (40.8%) (30.6%) (40.5%) (42.0%)
P4HB 20.1% 21.7% 21.6% 22.9% 20.2% 32.5% 24.50% 23.5%
(34.3%) (29.2%) (39.3%) (38.3%) (36.0%) (54.1%) (39.9%) (42.9%)
PDIA2 23.5% 20.8% 21.2% 20.6% 20.8% 28.6% 23.3.% 23.3% 47.3%
(35.5%) (38.7%) (31.8%) (38.7%) (32.1%) (49.0%) (37.2%) (37.7%) (64.5%)
PDIA3 21.7% 16.9% 21.5% 18.8% 21.4% 21.8% 22.3% 23.1% 33.6% 31.1%
(37.5%) (37.9%) (33.3%) (31.3%) (37.5%) (38.9%) (34.1%) (40.6%) (51.0%) (49.5%)
PDIA4 19.80% 19.7% 18.8% 21.4% 17.5% 18.3% 29.6% 24.0% 36.8% 29.1% 41.9%
(31.6%) (38.6%) (38.2%) (38.5%) (30.8%) (35.0)% (48.1%) (40.9%) (55.1%) (46.2%) (60.2%)
PDIA5 24.2% 22.1% 21.3% 21.7% 21.4% 19.6% 19.7% 22.6% 24.3% 23.1% 22.9% 21.2%
(45.1%) (44.1%) (35.1%) (36.9%) (40.0%) (33.5%) (33.9%) (40.6%) (38.3%) (35.0%) (37.1%) (31.5%)
PDIA6 27.6% 15.2% 24.0% 19.4% 32.7% 20.6% 17.0% 20.2% 23.5% 21.8% 24.2% 25.8% 28.1%
(35.2%) (57.6%) (40.6%) (33.1%) (48.0%) (34.8)% (32.2%) (38.4%) (31.4%) (28.6%) (33.4%) (40.0%) (43.1%)
PDILT 23.9% 16.2% 20.1% 21.1% 20.4% 29.7% 19.1% 21.9% 31.8% 32.1% 22.1% 26.0% 19.9% 23.5%
(45.7%) (35.9%) (43.4%) (41.8%) (36.1%) (54.1%) (38.5%) (40.9%) (52.4%) (51.3%) (37.1%) (46.7%) (35.3%) (36.3%)
TMX1 18.6% 24.8% 23.7% 17.2% 21.1% 23.9% 15.5% 25.8% 29.9% 25.7% 30.0% 25.1% 35.0% 36.2% 27.0%
(36.1%) (36.0%) (37.8%) (29.9%) (38.2%) (39.4%) (32.3%) (49.0%) (46.9%) (40.0%) (50.0%) (41.3%) (56.4%) (59.0%) (39.3%)























Table 2 Amino acid similarity between human PDI proteins, as reported using EMBOSS Water Pairwise Alignment Algorithm (http://www.ebi.ac.uk/Tools/psa/
emboss_water/) (Continued)
(36.1%) (33.1%) (39.9%) (44.4%) (44.8%) (41.5%) (43.6%) (38.0%) (40.9) (44.6%) (36.9%) (43.7%) (34.9%) (38.9%) (42.9%) (43.1%)
TMX3 20.0% 19.7% 20.3% 21.8% 22.4% 18.1% 20.5% 21.4% 27.8% 21.6% 23.1% 27.1% 23.5% 45.3% 19.2% 34.2% 18.7%
(37.4%) (36.5%) (43.0%) (43.6%) (44.1%) (33.3%) (35.7%) (34.7%) (47.9%) (40.3%) (41.1%) (42.7%) (41.2%) (64.2%) (32.2%) (50.5%) (38.4%)
TMX4 23.5% 25.7% 27.0% 23.1% 23.7% 28.6% 19.5% 20.1% 21.8% 24.9% 24.3% 20.5% 27.2% 24.0% 25.0% 43.6% 24.4% 22.4%
(39.5%) (36.6%) (62.2%) (47.3%) (39.4%) (42.9%) (36.0%) (37.0%) (34.4%) (37.0%) (45.7%) (32.1%) (41.6%) (37.1%) (42.5%) (65.0%) (42.2%) (34.2%)
TXNDC5 21.6% 20.9% 22.9% 20.7% 25.4% 22.0% 20.8% 33.3% 26.2% 26.9% 24.4% 23.5% 27.3% 33.0% 23.3% 24.6% 29.5% 51.4% 21.6%
(28.4%) (39.5%) (37.9%) (34.0%) (41.5%) (37.9%) (32.9%) (50.0%) (37.2%) (37.5%) (38.5%) (34.1%) (43.8%) (53.0%) (34.9%) (33.8%) (50.0%) (71.6%) (38.0%)
TXNDC12 34.2% 38.3% 20.0% 41.2% 18.5% 20.2% 27.5% 21.1% 26.2% 26.9% 24.1% 22.9% 22.7% 26.9% 23.1% 27.7% 21.6% 31.9% 18.7% 20.1%
(50.6%) (53.9%) (30.8%) (70.6%) (36.3%) (30.2%) (40.0%) (32.2%) (37.2%) (37.5%) (39.7%) (41.2%) (43.8%) (37.0%) (38.2%) (39.8%) (37.4%) (48.9%) (32.1%) (31.5%)
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glucose-regulated protein 78 (GRP78 or BiP) [16].
ERP29 has been postulated to play a role in the progres-
sion of tumorigenesis in mice; following implantation of
both knockdown and over-expressed null ERP29 MCF-7
cells, a significant decrease in tumor size and altered
morphogenesis was observed in mice [17]. Currently, no
knockout mouse is available for Erp29.
ERP44
The ERP44 gene is located at Chr 9q22.33 and encodes
the 406-a.a. ERP44 protein [18]. ERP44 was discovered
following immunoprecipitation experiments with human
endoplasmic reticulum oxidoreductase-1α (ERO1-Lα)
and was originally identified as KIAA0573 [18]. The cod-
ing sequence of ERP44 contains 12 exons and there is an
ERSE in the promoter region of the gene [18]. The
human ERP44 protein contains an unverified NH2-ter-
minal signal peptide (29 a.a.), three TRX-like domains
(one being the catalytically active a domain with a Cys-
Arg-Phe-Ser active site), and the ER-retention sequence
(Arg-Asp-Glu-Leu) [18]. The precise physiological func-
tion of ERP44 has yet to be determined; however, oxida-
tion of ERO1α has been observed, suggesting that
ERP44 may control the function of the ERO1 proteins,
thus controlling the redox state of the ER [18]. ERP44 is
up-regulated during ER stress response and has also
been proposed to play a role in adiponectin secretion
which influences glucose regulation and fatty acid catab-
olism [18,19].
P4HB
P4HB is the first described member of the PDI gene
family and was originally identified as the β-subunit of
human prolyl-4-hydroxylase (P4H) [20,21]. The P4HB
gene is located at Chr 17q25 and consists of 11 exons
[20,22]. The promoter region of P4HB contains 11 pro-
tein binding sites, including an ERSE, underscoring the
dynamic nature of P4HB transcriptional regulation [23].
Although the presence of an ERSE has been confirmed
in the promoter region of the gene, P4HB is considered
to be a weakly-induced ER stress protein, likely due to
its high abundance. The promoter region also contains
six CCAAT elements in the first 378 nt of the gene, and
mutations introduced into any of these elements was
found to reduce promoter activity by up to 50% [23].
The P4HB gene encodes a 508-a.a. protein containing
a 17-a.a. signal peptide, four TRX domains with two a
type (Cys-Gly-His-Cys, Cys-Gly-His-Cys), an Asp/Glu
rich domain (a.a. 480 to 500), and a COOH-terminal ER
retention sequence (Lys-Glu-Asp-Leu) [2]. P4HB is ubi-
quitously expressed in nearly all tissues and is very
highly abundant; estimations predict P4HB to account
for up to 0.8% of total cellular protein [24]. Currently, acrystal structure has yet to be resolved for the full, intact
protein, although multiple domains have been solved.
Despite this, P4HB remains the most widely studied and
understood protein in the family. P4HB is effective at
oxidizing, reducing, and isomerizing disulfide bonds
both in vitro and in vivo and exists as a homodimer
[25,26]. Although its role in disulfide bond generation
remains the most widely studied enzymatic action,
P4HB has also been shown to exhibit chaperone-like ac-
tivity, demonstrating an additional role in maturation of
nascent proteins regardless of the presence of disulfide
bonds [27,28]. P4HB has also been shown to be an es-
sential subunit for microsomal triglyceride transfer pro-
tein and P4H [21,29]. To date, no viable knockout
mouse strain for P4hb has been reported, likely due to
its critical role in disulfide bond generation [3].
PDIA2
PDIA2 was identified in 1996 as a pancreas-specific
member of the PDI family, resulting in its common
name, PDIp [30]. Located on Chr 16p13.3, the initial
characterization of the PDIA2 gene revealed that it
encodes a protein with an ORF of 511 a.a; these studies
were unable to validate an in-frame stop codon located
5′ upstream of the ATG start site [30]. Due to this dis-
crepancy, the PDIA2 sequence was verified in 2006 to
have an NH2-terminal signal sequence, generating a pro-
tein of 525 a.a. in length. The PDIA2 gene also yields
two splice variants encoding two isoforms of the mature
PDIA2 protein, varying by three amino acids in length
(isoform 2 does not contain a.a. 181 to 183). Multiple
SNPs have been detected in the PDIA2 gene, resulting in
mutations at a.a. 39 (Pro! Ser), 119 (Thr!Arg), 185
(Glu!Lys), 286 (Thr!Met), 382 (Pro!Ala), 388 (Arg
!Gln), and 502 (Pro! Ser).
The PDIA2 protein contains two a type (Cys-Gly-His-
Cys and Cys-Thr-His-Cys active sites) and one b and
one b’ type domains; although redox active, PDIA2 was
found to be less effective than P4HB in assays for both
reduction and oxidation of disulfides [30]. In addition to
its role as a folding catalyst, PDIA2 has been proposed
to play a role in the production and secretion of digest-
ive enzymes in vivo [31]. Evidence has also suggested a
role for PDIA2 in the binding and regulation of intracel-
lular 17β-estradiol levels, thus regulating estrogen syn-
thesis [32]. PDIA2 contains three sites for Asn-linked
glycosylation, located at residues 127, 284, and 516 [30].
To date, no knockout studies have been conducted with
Pdia2.
PDIA3
Originally identified as phospholipase C alpha, the
PDIA3gene, located at Chr 15q15, encodes the 505-a.a
PDIA3 protein (also commonly known as ERp57, ERp60,
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tains a signal peptide, corresponding to the first 24 a.a.,
yielding a mature protein of 481 a.a. in length [34].
PDIA3 contains two a type (Cys-Gly-His-Cys and Cys-
Gly-His-Cys active sites), one b and one b’ type domain
and an ER retention sequence, Gln-Glu-Asp-Leu [35,36].
PDIA3 expression has been detected in liver, placenta,
lung, pancreas, kidney, heart, skeletal muscle, brain, and
spermatozoa [33,37]. Presently, only one missense SNP
has been reported for PDIA3, resulting in a mutation of
Lys!Arg at a.a. 415.
The precise physiological role of PDIA3 has come under
much scrutiny. Following the initial characterization of the
protein in vitro, PDIA3 (termed ERp60 or P58 at the time)
was identified as a cysteine protease despite little sequence
homology with other heavily studied cysteine proteases
[35]. In 1995, however, PDIA3 was determined to be redox
active, showing the ability to reduce insulin disulfides.
Bourdi et al. were also able to definitively prove that
PDIA3 possessed no protease activity [36]. PDIA3 has also
been shown to play a role in the correct folding of glyco-
proteins when in a complex containing both calnexin and
calreticulin [38]. The physiological role of PDIA3 has also
been investigated in rodent models, utilizing Pdia3(−/−)
knockout mice. Although ubiquitous deletion of Pdia3
was found to be embryolethal, heterozygous knockouts
were generated, revealing multiple bone abnormalities,
most notably in the femur [39]. Ablation of Pdia3 was
found to abolish signaling induced by 1,25-dihydroxyvita-
min D3, a crucial regulator of bone and cartilage develop-
ment, by eliminating signaling through protein kinase C
[39]. Additional knockout studies in murine B cells
revealed a critical role for PDIA3 in the presentation of
antigens by major histocompatibility complex I molecules
[40]. Although additional work is needed, these studies
suggest a wide array of physiological roles for PDIA3.
PDIA4
PDIA4 is located at Chr 7q35 and encodes the 645-a.a.
PDIA4 protein (commonly known as ERp72). Although
not much is known about the physiological role of
PDIA4, studies indicate that this gene is induced follow-
ing ER stress; these results have been found to be the re-
sult of a putative ERSE in the promoter region of the
gene [41,42]. Like other PDI family members, PDIA4
contains an NH2-terminal signal peptide of 21 a.a., yield-
ing a mature protein of 625 a.a. [43]. PDIA4 contains
five TRX domains, three a type (with all three active
sites being comprised of Cys-Gly-His-Cys), one b and
one b’ type; PDIA4 also contains the ER retention se-
quence (Lys-Glu-Glu-Leu) [43,44]. Mutagenesis studies
to the active-site cysteines revealed varying degrees of
decreased enzymatic activity, whereas mutagenesis to
multiple domains revealed a more pronounced reductionin enzymatic activity of the protein [44]. PDIA4 also
contains a string of highly acidic residues near the NH2-
terminus of the protein; while the precise role of these
residues remains unknown, they have been proposed to
play a role in regulation of Ca2+, yielding its rat homolog
name calcium-binding protein-2 (CaBP2) [45]. PDIA4 is
a fairly ubiquitously expressed protein, although less
abundant than PDI, expression patterns are similar to
those of PDIA3 [46]. One missense SNP has been
reported in the PDIA4 gene, resulting in a mutation
located at residue 173 (Thr!Met). Studies analyzing
Pdia3 knockdown revealed partial functional restoration
by the PDIA4 protein, although, to date, no Pdia4
knockout mouse has been generated [47].
PDIA5
Although discovered in 1995, little is known about the
precise role of the PDIA5 gene. Located on Chr 3q21.1,
PDIA5 encodes the 519-a.a. PDIA5 (or PDI-related pro-
tein). PDIA5 contains four TRX domains (three a and one
b-like domain), made up of active sites Cys-Ser-Met-Cys,
Cys-Gly-His-Cys and Cys-Pro-His-Cys, a COOH-
terminal ER retention sequence (Lys-Glu-Glu-Leu),
and an unverified signal sequence comprising the
first 21 a.a. [48]. Despite an additional Cys-X-X-Cys
motif, Horibe et al. revealed that PDIA5 has signifi-
cantly less enzymatic activity than that of P4HB [49].
The contributions of each Cys-X-X-Cys active site
were also investigated, revealing varying degrees of
altered activity following mutations to each, or mul-
tiple, active sites [49]. It was concluded that the sec-
ond active site (Cys-Gly-His-Cys) was the most
critical for isomerase activity and that all three
motifs are not required for activity [49]. Much like
P4HB, PDIA5 was also shown to exhibit chaperone-like ac-
tivity by refolding denatured rhodenase, which does not
contain any disulfide bonds [49]. PDIA5 mRNA has been
detected in liver, kidney, lung, and brain––with the highest
level of secretion being noted in the liver [48]. Although to
date no ERSE has been identified, PDIA5 has been shown
to be moderately up-regulated following induction of the
ER-stress response in cultured cells [48]. In a 2011 study by
Carbone et al., a significant association was found between
the SNP, rs11720822, and primary open-angle glaucoma in
two separate populations [50]. No viable knockout mouse
has been generated for Pdia5.
PDIA6
Much like PDIA5, little is known about the role of
PDIA6 both in vitro and in vivo. The PDIA6 gene is
located at Chr 2p25.1 and encodes the 440-a.a. PDIA6
protein (commonly reported as P5 or ERP5). PDIA6
contains an NH2-terminal signal sequence of 19 a.a.,
three TRX domains (two a type and one b) consisting of
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main and a COOH-terminal Lys-Asp-Glu-Leu ER-
retention sequence [51,52]. Recombinant PDIA6 demon-
strates both isomerase and chaperone activities, although
approximately 45% and 50% to 60% to that of P4HB, re-
spectively [53]. Point mutations have also been con-
ducted to the active-site cysteines, revealing that NH2-
terminal cysteines in each active site exhibit the majority
of isomerase activity [53]. PDIA6 contains an ERSE in its
promoter region, which was recently validated in vitro
utilizing over-expression of the ER-stress transcription
factor, X-box protein-1 (XBP-1); PDIA6 was found to be
significantly increased, demonstrating inducibility by the
unfolded protein response [54,55]. A complete expres-
sion profile for PDIA6 has yet to be conducted; however,
high levels of the protein were detected in platelets.
Cell-surface expression of PDIA6 was found to be neces-
sary for the proper development and function of plate-
lets, whereas inhibition of the protein using anti- PDIA6
antibodies revealed inhibition of platelet aggregation
[51]. PDIA6 has also been shown to directly interact
with GRP78 (or BiP) suggesting a role for PDIA6 in the
refolding of substrates that have been targeted to BiP
[56]. Presently, one missense SNP has been identified
(rs4807) resulting in a point mutation at a.a. 214 (Lys!
Arg). At present, no viable Pdia6 knockout mouse is
available.
PDILT
Expression of the PDILT gene has been reported to be ex-
clusively limited to the testis. PDILT is located on Chr
16p12.3, encoding the 584-a.a. PDILT protein [57]. Des-
pite the presence of two a type TRX domains (with non-
classical Ser-Lys-Gln-Ser and Ser-Lys-Lys-Cys motifs),
PDILT does not exhibit the ability to oxidize or reduce di-
sulfide bonds, although evidence has supported PDILT to
engage in disulfide-bonded complexes in vitro [57,58].
PDILT contains a predicted NH2-terminal signal peptide
of 20 a.a. in length, a COOH-terminal ER-retention se-
quence (Lys-Glu-Glu-Leu) and is heavily glycosylated
through nine potential Asn-linked glycosylation sites [57].
Much like P4HB, PDILT also interacts with the oxidore-
ductase ERo1α in cultured cells, suggesting a role in the
shuffling of electrons in the ER lumen [57]. No knockout
mouse is currently available and considerable research is
needed to fully elucidate the precise role of PDILT.
TXNDC5
TXNDC5 is located at Chr 6p24.3 and encodes the
432-a.a. endothelial PDI, TXNDC5 (or EndoPDI) protein
[59]. Despite its discovery in 2003, little research has been
conducted on the role of TXNCD5 in vivo. TXNDC5 con-
tains a signal peptide of 32 a.a., three a-type TRX
domains all with Cys-Gly-His-Cys active sites, and aCOOH-terminal ER retention sequence, KDEL [59].
TXNDC5 was originally identified in a screen for
proteins highly expressed in endothelial cells, leading
to its common name, EndoPDI. Subsequent studies
revealed TXNDC5 expression in a number of tissues
with the highest expression being found in lymph
nodes, stomach, pancreatic islets, and heart [59,60].
TXNDC5 is induced under conditions of hypoxia,
and loss of TXNDC5 leads to an increase in apop-
totic cell death in microvascular endothelial cells
during hypoxia, but not normoxia [59]. Preliminary
studies have also implicated a role for TXNDC5 in
diabetes, noting a decrease in the expression of the
protein in pancreatic islets in animals with consistently ele-
vated glucose levels [60]. In a 2010 study, Jeong et al. inves-
tigated the role of TXNDC5 in development of the skin
disorder vitiligo [61]. A total of 230 Korean patients with
non-segmental vitiligo were investigated for SNPs in the
TXNDC5 gene; in total, seven SNPs were identified in the
TXNDC5 gene, three of which (rs1043784, rs7764128, and
rs8643) demonstrated an association with the vitiligo
phenotype [61]. Although relevant in vivo studies have been
conducted on the role of TXNDC5 no biochemical para-
meters have been evaluated, with regard to its role in disul-
fide bond oxidation and reduction. A viable knockout
mouse has not been generated for the study of Txndc5.
The anterior gradient homolog genes
AGR2
The AGR2 gene is located at Chr 7p21.3 and encodes the
175-a.a. anterior gradient protein 2 homolog (AGR2)
[62,63]. The AGR2 protein has an NH2-terminal signal se-
quence of 20 a.a., one TRX domain (with active site Cys-
Pro-His-Ser), and a COOH-terminal ER-retention se-
quence (Lys-Thr-Glu-Leu) [63]. Human AGR2 was origin-
ally identified in estrogen receptor-positive MCF7 cells
using suppression subtractive hybridization [64]. Expres-
sion of AGR2 transcripts has been detected in lung, pan-
creas, trachea, stomach, colon, prostate, and small
intestine. AGR2 has also been investigated as a potential
biomarker for hormone-responsive breast cancer in estro-
gen receptor-α-positive breast cancer cell lines [64].
Utilizing knockout studies in mice, the Agr2 gene was
found to result in the inability to produce mucin, leading
in an increased susceptibility to experimentally induced
colitis and intestinal disease [65]. Due to its role in disul-
fide bond generation, it was hypothesized that AGR2 was
responsible for the processing of MUC2, the major intes-
tinal mucin. This protein contains >200 cysteine residues
involved in various inter- and intra-protein disulfide
bonds and has been found to directly associate with
AGR2 [65]. Following this report, Zheng et al. investi-
gated AGR2 and AGR3 as potential candidate genes for
inflammatory bowel disease in humans [66]. A cohort of
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disease was investigated for SNPs in AGR2 and AGR3; in
total, 30 SNPs were identified, 25 were located in the
AGR2 gene, while 5 were located in the AGR3 gene [66].
The promoter region of the AGR2 gene was also found
to contain binding sites for hepatic nuclear factor-1, hep-
atocyte nuclear factor 3-α (FOXA1) and hepatocyte nu-
clear factor 3-β (FOXA2)––transcription factors that
have been reported to play a role in the morphogenesis
of goblet cell differentiation during formation. In sum-
mary, two total SNPs in the 5′ promoter region of the
AGR2 gene were found to be associated with the risk
haplotype of ulcerative colitis in two independent popu-
lations, providing further evidence for a role for AGR2
in disease pathogenesis [66].
AGR3
The AGR3 gene is located at Chr 7p21.1 and encodes
the 166-a.a. anterior gradient protein-3 (AGR3) homolog
[63]. AGR3 transcripts have been detected in lung and
pancreas and, resembling AGR2, AGR3 has been
reported to be co-expressed with estrogen receptor-α-
containing breast cancer cell lines, suggesting it to be a
marker for hormone-responsive breast cancer [63,64].
Unlike AGR2, however, little is known about the precise
physiological role of AGR3. AGR3 protein was originally
identified as breast cancer membrane protein 11
(BCMP11), following a proteomic screen of membrane
proteins in breast cancer cell lines, and was later named
AGR3 due to the high degree of sequence homology
with AGR2 (see Table 2) [67]. Like AGR2, AGR3 con-
tains one redox-active center, comprised of amino acids
Cys-Gln-Tyr-Ser, an NH2-terminal signal peptide com-
posed of 21 a.a., and a COOH-terminal ER-retention se-
quence (Gln-Ser-Glu-Leu) [63]. Recently, an increase in
AGR3 expression was observed in serous border-line
ovarian tumors and low-grade serous ovarian carcinoma
[68]. Utilizing Kaplan-Meier survival curves, King et al.
also established that patients with AGR3-expressing
tumors survived significantly longer than those patients
lacking AGR3-expressing tumors [68].
TXNDC12
TXNDC12, also known as AGR1, TLP19, and ERP18/19,
contains conserved intron positions with respect to amino
acid sequence with the AGR2 and AGR3 genes [63]. Pers-
son et al. also reported that several of the individual exon
lengths are identical (or altered with one codon) to AGR2
and AGR3 [63]. TXNDC12 has been mapped to Chr
1p32.3 and contains seven exons spanning more than
35 kb [69]. TXNDC12 is ubiquitously expressed in all tis-
sues, with the highest expression being found in the liver
and placenta. TXNDC12 in the placenta was found to
express an additional transcript of 1.2 kb which isassociated with two poly(A) addition signals in its 3′-UTR
[69]. The TXNDC12 protein contains 172 a.a. with 149 a.a.
comprising the mature form of the protein (Ser24 – Leu172);
TXNDC12 has one active site comprised of Cys-Gly-
Ala-Cys and an ER-retention sequence (Glu-Asp-Glu-Leu)
[70]. Unlike the other members of the AGR subfamily, ex-
tensive work has been conducted on the biochemical and
physiochemical actions of TXNDC12. The enzymatic activ-
ity of TXNDC12 has been found to be limited strictly to di-
sulfide bond generation and not reduction; these studies
were also confirmed with the use of point mutations to the
active-site cysteines (Cys-Gly-Ala-Cys), after which no de-
tectable activity was found [70]. Chemical denaturation
curves were also found to favor greater protein stability in
the reduced form over the oxidized form, a property con-
sistent with other PDI family members [70].
The CASQ genes
The CASQ genes (1 and 2) are interesting members of
the PDI family, possessing no cysteine containing redox-
active sites and therefore playing no role in the forma-
tion or reduction of disulfide bonds. As indicated, many
of the PDI family proteins bind Ca2+ with relatively high
capacity and low affinity [71]. Following studies on
CASQ, Shin et al. found that the COOH-terminal Asp-
rich domain played a major role in storage of Ca2+
through interaction with ryanodine receptor (RYR), a
protein involved in Ca2+ release from the sarcoplasmic
reticulum (SR) [72]. These proteins, therefore, possess
unique functions relating to the PDI family of proteins,
despite limited sequence homology.
CASQ1
The CASQ1 gene is located on Chr 1q21 and encodes
the 396-a.a. CASQ1 protein [73]. Expression of the ma-
ture CASQ1 protein is primarily limited to the SR of
fast-twitch skeletal muscles [74]. Studies in rabbit have
revealed CASQ1 to be a high-capacity (40 to 50 Ca2+
per molecule of CASQ1), moderate-affinity (Kd = 1 mM)
Ca2+-binding protein that does not contain an ER-
retention sequence [74-76]. Although experimentally un-
verified, the first 34 a.a. of CASQ1 encode the signal
peptide, leaving the mature protein at 362 a.a. in
length––which contains three TRX domains (two b and
one b’) and a string of highly acidic residues from a.a.
353 – 396. Like other members of the PDI family, these
Asp/Glu-rich stretches of a.a. are thought to be the pri-
mary binding regions for Ca2+; CASQ1 plays a major
role in Ca2+ flux through the regulation of Ca2+ channel
activity and interaction with Ca2+ directly [72]. Systemic
knockout studies in mice revealed hypersensitivity to
heat and volatile anesthetics, along with a phenotypic re-
semblance to malignant hyperthermia [77]; these effects
were found to be due to increased Ca2+ following an
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one potential Asn-linked glycosylation site, found at a.a.
350.
SNPs in the CASQ1 gene have been reported in cases of
diabetes in both Old-Order Amish and Northern Euro-
pean Caucasians [79,80]. Out of 26 identified SNPs, SNP
CASQ-1404 (rs1186694) in the 5′ flanking region was
found to have a statistically significant association with
type-2 diabetes in Northern European Caucasians [79]. In
a similar study analyzing type-2 diabetes susceptibility in
Old-Order Amish populations, SNPs rs2275703 and
rs617698 were defined as the ‘at-risk alleles’ [80]. Although
mechanistically these correlations have not been con-
firmed, previous work has identified a putative role for
Ca2+ release from the SR into the cytosol in regulating glu-
cose transporter-4 (GLUT4), a key enzyme in regulation
of glucose transport by insulin [80,81].
CASQ2
The CASQ2 gene is located on Chr. 1p13.3-p11, and likely
is the result of gene duplication with CASQ1––given their
chromosomal location. CASQ2 encodes the 399-a.a.
CASQ2, which shares 91% identity with its homologue,
CASQ1 (see Table 2) [82,83] The CASQ2 protein is
expressed exclusively in cardiac muscle and serves as the
major Ca2+ reservoir in the SR of myocardium; CASQ2
also interacts with the RYR2 channel, regulating Ca2+ flux
from the SR [76,84]. Much like CASQ1, CASQ2 contains
an unverified NH2-terminal signal peptide (19 a.a.), three
b-like TRX domains (two b and one b’), no ER-retention
sequence, and a string of highly acidic residues (a.a. 356 to
399); CASQ2 does, however, contain one potential Asn-
linked glycosylation site at a.a. 355.
The CASQ2 gene has become a heavily researched tar-
get for diseases associated with arrhythmic heartbeats. In
2001, Lahat et al. investigated missense mutations found
in the coding region of the gene [83]. One SNP (G −> C)
was found to result in an aspartic acid changed to a histi-
dine at a.a. 307 of the mature protein, potentially altering
the Ca2+-chelating function of that region [83]. This SNP
was found to be associated with Bedouin families from Is-
rael susceptible to catecholine-induced polymorphic ven-
tricular tachycardia [83]. These studies were later
confirmed in Casq2(−/−) knockout mice, revealing sus-
ceptibility to polymorphic ventricular tachycardia follow-
ing exposure to catecholamines [85].
Thioredoxin-related transmembrane proteins
The thioredoxin-related transmembrane (TMX) genes
are newly discovered members of the PDI gene family.
To date, little is known about the precise function of
these genes; however, all four members in the PDI family
consist of one TRX domain, one transmembrane do-
main, and non-conventional ER-retention sequences.TMX1
Discovered in 2001, TMX1 is located at Chr 14q22.1 and
encodes the 280-a.a. TMX1 protein [86]. TMX1 contains
an NH2-terminal signal sequence of 26 a.a., one a-type
TRX domain with active site Cys-Pro-Ala-Cys, one
transmembrane domain (a.a. 183 to 203), and lacks an
ER-retention sequence [86]. Expression of TMX1 is
fairly ubiquitous, with highest levels detected in liver,
kidney, placenta, and lung [86]. Mature TMX1 possesses
the ability to both oxidize and reduce disulfide bonds,
although chaperone-like activity has yet to be investi-
gated [86,87]. The TMX1 gene does not contain a puta-
tive ERSE in the promoter region, supporting evidence
that TMX1 is not induced by numerous ER-stress-
inducing agents; over-expression of the protein in cul-
tured cells, however, has revealed amelioration of both
Brefeldin A-induced apoptosis and tunicamycin-induced
ER stress [86,88]. No knockout mouse has been gener-
ated for the study of Tmx1.
TMX2
Perhaps the least researched gene in the family, TMX2
was discovered in 2003 [89]. Located on Chr 11cen-q22.3,
TMX2 encodes the 296-a.a. TMX2 protein [89]. Like
TMX1, TMX2 contains a COOH-terminal signal peptide
(48 a.a.), one a-type TRX domain (Ser-Asn-Asp-Cys active
site), one transmembrane domain (a.a. 104 – 126), and an
ER-retention sequence comprised of Lys-Lys-Glu-Ile [89].
Expression of TMX2 is fairly ubiquitous––with high levels
detected in heart, brain, liver, kidney, and pancreas [89]. Al-
though Meng et al. provided the initial characterization of
the protein, sequence discrepancies have been found. The
official NCBI sequence of the TMX2 protein reveals a pro-
tein of 296 a.a and a second isoform, lacking an in-frame
exon in the central coding region, encoding a protein of
258 a.a (isoform 2 differs between a.a. 84 to 122). Future
studies are required to fully elucidate the role of TMX2
in vivo. The availability of a TMX2 knockout mouse has
not been reported.
TMX3
The human TMX3 gene is located at Chr 18q22 and
encodes the 454-a.a. TMX3 protein [90]. Following
cleavage of the 24-a.a. signal peptide, the 430-a.a. mature
protein consists of one a-type TRX domain, with the ac-
tive site being comprised of Cys-Gly-His-Cys, a trans-
membrane domain (located at a.a. 375 to 397), and the
ER-retention sequence (Lys-Lys-Lys-Asp) [90]. Unchar-
acteristic to most PDI family members, TMX3 contains
a luminal domain with weak sequence similar to that of
the CASQ proteins [90]. Although no research has been
conducted on the role of this domain in activity of the
protein, it has been postulated to regulate Ca2+ in a
manner similar to that of other CASQ proteins. NCBI
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protein), though experimentally this has not been vali-
dated [90]. TMX3 has been detected in brain, testis,
lung, skin, kidney, uterus, bone, stomach, liver, prostate,
placenta, eye, and muscle, with highest levels detected in
heart and skeletal muscle [90]. TMX3 contains two sites
of Asn-linked glycosylation (a.a. 258 and 313), which
have been validated in vitro and is not induced under
conditions of ER stress [90]. Although far less efficient
than P4HB, TMX3 does display the ability to oxidize di-
sulfide bonds; this is likely due to the presence of only
one Cys-Gly-His-Cys active site [90].
Although no knockout mouse has been generated for
TMX3, studies have been conducted in mice, targeting
TMX3 transcripts using morpholinos [91]. Investigating
the mechanisms behind microphthalmia in humans, a gen-
etic disease associated with retarded growth of the eye, a
2.7-Mb deletion was found at Chr 18q22.1, leading to dele-
tion of the TMX3 gene [91]. Studies in mice using a tar-
geted approach to delete the TMX3 gene revealed a similar
phenotype, which was rescued following injection of
human TMX3 mRNA [91]. Sequencing of 162 patients
with anopthalmia or microphthalmia revealed two mis-
sense mutations, leading to the missense SNPs, R39N, and
D108N [91]. Future studies are required to fully elucidate
the precise role of TMX3, although preliminary studies re-
veal exciting areas for research.
TMX4
The TMX4 gene is located at Chr 20p12 and encodes the
349-a.a. TMX4 protein [92]. TMX4 consists of an NH2-ter-
minal signal sequence (23 a.a.), one a-type TRX domain (a.
a. 39 – 136 with the active site comprised of Cys-Pro-
Ser-Cys), a transmembrane domain (a.a. 188 to 210), a
string of highly acidic a.a. (224 to 334), and (like the other
TMX proteins) lacks an ER-retention sequence [93]. TMX4
is ubiquitously expressed, with highest levels detected in
heart [92]. Preliminary studies show that TMX4 is not
induced following conditions of ER stress and does not
contain a putative ERSE in the promoter region of the gene
[92]. TMX4 contains one site of Asn-linked glycosylation
and two sites of Ser phosphorylation, which have all been
experimentally validated [93]. Enzymatic activity was con-
firmed by observing reduction of insulin disulfides; a
dominant-negative mutant, with the active-site cysteines
mutated to serine, displayed no enzymatic activity [92]. No
knockout mouse has been generated and substantial work
will be required to understand the role of TMX4 in vivo.
Conclusions
The PDI family of proteins consists of 21 members vary-
ing greatly in enzymatic activity, domain architecture,
and tissue specificity. Although the predominant role of
the PDI proteins is the regulation of protein foldingin vivo––through the oxidation, reduction and isomeri-
zation of disulfide bonds––these proteins have also been
shown to regulate calcium homeostasis in the ER and in-
duction of the unfolded protein response (UPR). Since
its discovery over 40 years ago, PDI has become one of
the most highly studied proteins and, despite these
advances, extensive research is still needed to fully
understand the role of PDI in vivo. The more recently
characterized TMX genes have displayed promise in
novel therapeutics, ranging from disorders of the eye to
regulation of the ER-stress response. Many of the genes
in the PDI family contain a putative ERSE sequence in
the promoter region of the gene, suggesting a role in the
UPR. Further research on the role of these proteins in
the UPR is required before effective therapeutics can be
generated for a plethora of disease states associated with
the ER-stress response. The 21 members of the PDI fam-
ily of proteins encompass many physiological responses,
and these proteins will likely provide compelling avenues
for future research.
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